Best of ASCO - 2014 Annual Meeting

 

Welcome

Ovarian Cancer

Gynecologic Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A 3D micro-tumor model capturing tumor heterogeneity of a patient's primary tumor biopsy.

Katya Nikolov

e17076

A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.

Deborah Kay Armstrong

5523

A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).

Kidong Kim

e17032

A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).

Karen Anne Cadoo

5511

A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.

Stephanie Lheureux

5518

A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.

Ignace Vergote

5537

A retrospective review on extended carboplatin infusion and incidence of hypersensitivity reaction in gynecologic malignancies in a single institution.

Jennifer Park

e17102

Accuracy of primary laparoscopic staging in patients with early ovarian malignancies: A retrospective multicenter study.

Julia Caroline Radosa

e17052

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Kathleen N. Moore

5513

Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.

Nicoletta Colombo

5539

AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).

Frederik Marme

TPS5601

An optimized homologous recombination deficiency (HRD) algorithm ASGAD for predicting PARP inhibitor response in ovarian cancer patient.

Yang Jiao

e17077

ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.

Oloruntoba Ismail Osagie

e17036

Association between time to first subsequent therapy (TFST) and overall survival (OS) in previously untreated patients with ovarian cancer (OC): A SEER Medicare database analysis.

Kaushal Desai

e17095

Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer.

J.P. P. Grabowski

5577

Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Rebecca Ann Previs

5557

Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).

Michele Bartoletti

5564

Bovine milk-derived exosomes mediated delivery of resibufogenin and its effect on platinum-resistant ovarian carcinoma.

Guannan Zhou

e17065

BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.

Caterina Fumagalli

5572

CD49d (high) T cells in the ovarian cancer microenvironment are a potential target for the optimization of immune checkpoint therapy in ovarian cancer.

Henning De May

e17075

Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer.

Yang Xiang

5543

Clinical benefit of bevacizumab in Mexican ovarian cancer patients according to the intention of treatment by the oncologist.

Dolores Gallardo-Rincon

e17097

Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea.

Hee Yeon Lee

e17062

Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.

Luisa Bonilla

5580

Clinical outcomes of postoperative intraperitoneal chemotherapy for patients with early-stage high-grade serous ovarian cancer (HGSC) treated at British Columbia cancer agency.

Joohyun Lee

e17105

Clinicopathologic features and prognostic analysis of stage I ovarian clear cell cancer.

Tian Tian Wang

e17090

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

Mansoor Raza Mirza

5505

Comprehensive genomic analysis of mucinous ovarian cancer reveals unique therapeutic vulnerabilities.

Dane Anthony Cheasley

5571

Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer.

Nicole D. Fleming

5570

Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer.

Ross Harrison

5556

Delay in time to adjuvant chemotherapy and its impact on outcome in completely resected advanced ovarian malignancies treated with CRS, CRS+IP and CRS +HIPEC.

Ashwin K Rajgopal

e17051

Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.

Ying L Liu

5552

Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, phase II trial.

Rongyu Zang

5514

DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression.

Janos Laszlo Tanyi

5576

DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Philipp Harter

TPS5598

Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies.

Elena Ioana Braicu

e17091

E-consult: To better inform patient.

Jean-Francois LE Brun

e17049

Effect of estrogen and progesterone receptor expression on progression-free and overall survival outcomes in low-grade serous ovarian cancer.

Marta Llaurado Fernandez

5560

Effects of bevacizmab, eribulin and oxaliplatin in relapsed patients with platinum-resistant and refractory ovarian carcinomas: A preliminary case series with biomarker evaluation.

Jin Suminokura

e17059

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

Wendy M Swetzig

5538

Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.

Michael Friedlander

5551

Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.

Mansoor Raza Mirza

5568

ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.

Antonio González-Martín

TPS5599

ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

Ignace Vergote

TPS5603

ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).

Anne-Claire Hardy-Bessard

TPS5600

EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.

Nicole Concin

TPS5605

Everolimus plus letrozole treatment of recurrent gynecologic cancers.

Kenneth David Miller

5567

Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.

Stephanie Lheureux

5521

EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

Claire Falandry

5508

Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.

Robert L. Coleman

5522

Exploring racial disparities of actionable mutations in gynecologic cancers.

Vasanti Jhaveri

e17098

Factors associated with extended survival for patients with platinum-resistant ovarian cancer treated with modified vaccinia oncolytic virotherapy.

Madhavi Manyam

e17070

Factors associated with one-year mortality after debulking surgery in older women with ovarian cancer.

Olga T. Filippova

e17069

First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.

Toshio Shimizu

5544

FLABRA, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population: A Latin America (LA) epidemiologic study.

Susana Beatriz Goncalves

e17050

Glucocorticoid receptor expression in Müllerian carcinosarcomas.

Meghan Steiner

e17038

GPR30 signaling to regulate epithelial-mesenchymal transition and predict survival in ovarian cancer.

Satoe Fujiwara

e17041

Half-dose olaparib reduction: Safe and efficient dose in multi-treated Mexican ovarian cancer patients.

Dolores Gallardo-Rincon

e17101

How do we bridge the gap? persistent differences in the preoperative experience for patients with gynecologic cancer treated at a public hospital.

Deanna Gerber

e17074

How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).

Felicia Roncolato

5549

Hypermetabolic activity by FDG-PET after immunogenic chemotherapy and multi-peptide immunotherapy in ovarian cancer.

Juan Pablo Marquez-Manriquez

e17079

Identification of prognostic variables in advanced ovarian cancer based on real-world patients from big data analytics.

Jesús García-Donas

e17104

Impact of a structured quality management program on survival of patients with advanced (AOC) and relapsed ovarian cancer (ROC) treated in a dedicated tertiary gynecologic-oncology (GO) center.

Philipp Harter

e17048

Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

Gwenael Ferron

5512

Impact of BRCA mutation status and time to platinum resistance on patients with advanced ovarian cancer.

Alexandra Tyulyandina

5561

Impact of the Affordable Care Act on early-stage diagnosis and treatment for women with ovarian cancer.

Anna Jo Smith

LBA5563

Incorporation of HIPEC into a high volume ovarian cancer program: Initial results and outcomes.

Aliza L. Leiser

e17040

Increasing potency and safety of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer.

Borhane Annabi

e17068

Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

Cara Amanda Mathews

5541

Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study.

Florence Joly

5555

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.

David M. O'Malley

5520

Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in ovarian cancer patients: Data from CHIVA trial (a GINECO study).

Patrick Robelin

5546

Molecular stratification of endometrioid ovarian carcinomas.

Barbara Stanley

5553

Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer.

Melissa Kristen Frey

5569

Multiple genetic alterations to predict the clinical outcome for bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.

Nan Du

e17037

Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network.

Julian Schink

e17067

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: An institutional experience.

Kavitha Jain

e17044

New biomarkers to predict platinum resistance in ovarian cancer patients.

Oana Trifanescu

e17085

Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect.

Yael Chava Cohen

5542

Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.

Lingying Wu

5554

Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Richard T. Penson

5506

Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the British Columbia (BC) cancer experience.

Shiru Lucy Liu

5536

Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.

Genevieve Bouchard-Fortier

e17093

Patient preferences for maintenance PARP therapy in ovarian cancer treatment.

Laura Jean Havrilesky

5558

Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.

John B. Liao

5519

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).

Haider Mahdi

TPS5602

Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.

Anna Tinker

TPS5604

Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.

Emily Hinchcliff

TPS5606

Poly adenosine diphosphate ribose polymerase inhibitors maintenance in patients with ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.

Thura WIN Htut

e17081

Predictive factors of cytoreductive surgery in epithelial ovarian cancer in a Mexican women cohort.

Flavia Morales Vasquez

e17099

Prognosis of ovarian cancer in the United States during 1973 to 2015.

Jianfeng Zhang

e17072

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery.

Laura Vincent

e17060

Prognostic implications of lymph node metastasis in advanced ovarian cancer: Analysis of the National Cancer Database 2006 to 2014.

Mohamed Elgamal

e17042

Prognostic value of monocyte to lymphocyte ratio (MLR) in epithelial ovarian cancer (EOC).

Marc Cucurull

e17066

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.

Adriaan Vanderstichele

5507

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) 50 mg/m2 and 40 mg/m2 in patients with platinum-resistant Müllerian carcinoma (JGOG3018).

Akira Yabuno

5550

Real life efficacy and safety data of bevacizumab-based front line treatment in advance or metastatic ovarian cancer patients: Focus on patients with malignant ascites—A phase IV study.

Michail Nikolaou

5562

Real time FTIR spectroscopy of tissue smears from gynecologic cancer tissues: A preliminary study.

Ilan Bruchim

e17089

Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment.

Frederique C. van der Scheun

5566

Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.

Matthew J. Monberg

5578

Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients.

David Garofalo

5579

Real-world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC).

David Garofalo

e17103

Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.

Melinda Louie-Gao

5547

Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study.

Isabelle Laure Ray-Coquard

5540

Rethinking breast cancer surveillance in women with BRCA-associated ovarian cancer in the post-solo trial era.

Catherine S. John

5565

Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.

Shannon Neville Westin

5548

Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy.

Katherine Tucker

e17035

Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy.

Stuart-Allison Moffat Staley

e17030

Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models.

Jennifer Taylor Veneris

e17039

Serum calretinin as a predictor for recurrence and overall survival in ovarian cancer.

Pauline Wimberger

e17033

SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).

Juliet Elizabeth Wolford

5545

Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer).

Alice Bergamini

5516

Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials.

Bradley Corr

5559

T cell trafficking within the peritoneal tumor environment and ovarian cancer progression.

Sharina Palencia Desai

5573

Telomere length and its implication as prognostic marker in ovarian cancer patients.

David M. Atallah

e17055

The association of marital status, socioeconomic status, and race on the survival of ovarian cancer patients.

Austin Blake Gardner

e17056

The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.

Allen Lee Cohn

5574

The developmental origins of high grade serous ovarian cancer.

Pietro Lo Riso

e17063

The effects of Wnt inhibition on tumor progression and the tumor microenvironment in a syngeneic mouse model of ovarian cancer.

Whitney Goldsberry

e17078

The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG).

Eiji Kondo

5515

The role of macrophage production of transforming growth factor-ß in epithelial ovarian cancer progression.

Brandon Roane

e17100

Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study.

Emil Lou

5581

Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.

Stuart-Allison Moffat Staley

e17031